• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Hypercalcemia Of Malignancy - Pipeline Review, Q3 2011 - Product Image

Hypercalcemia Of Malignancy - Pipeline Review, Q3 2011

  • ID: 1845442
  • July 2011
  • 37 pages
  • Global Markets Direct

Hypercalcemia Of Malignancy - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Hypercalcemia Of Malignancy - Pipeline Review, Q3 2011', provides an overview of the Hypercalcemia Of Malignancy therapeutic pipeline. This report provides information on the therapeutic development for Hypercalcemia Of Malignancy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercalcemia Of Malignancy. 'Hypercalcemia Of Malignancy - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypercalcemia Of Malignancy.
- A review of the Hypercalcemia Of Malignancy READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypercalcemia Of Malignancy Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercalcemia Of Malignancy
Hypercalcemia Of Malignancy Therapeutics under Development by Companies
Hypercalcemia Of Malignancy Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Hypercalcemia Of Malignancy Therapeutics - Products under Development by Companies
Hypercalcemia Of Malignancy Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hypercalcemia Of Malignancy Therapeutics Development
Amgen Inc.
Med Discovery SA
Hypercalcemia Of Malignancy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Xgeva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Parathyroid Hormone-Related Protein (1-36) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Parathyroid Hormone (1-34) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDAB16 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercalcemia Of Malignancy Therapeutics – Drug Profile Updates
Hypercalcemia Of Malignancy - Featured News
Dec 02, 2009: Genta to Support Initiation of New Clinical Trial using Ganite as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis
Jun 04, 2007: Phase 2 Clinical Results of Ganite® Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Mar 07, 2007: Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganite® and Genasense®
Mar 02, 2006: Randomized Trial Shows Ganite® Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia
Dec 05, 2004: Ganite® Activity in Patients with Advanced Non-Hodgkin's Lymphoma Presented at Hematology Meeting
Mar 25, 2004: GenasenseTM and GaniteTM Featured in Presentations at the Annual Meeting of the American Association for Cancer Research
Sep 18, 2003: FDA Approves Genta's First Product, Ganite, for the Treatment of Cancer - Related Hypercalcemia
Apr 10, 2003: New Study Shows Biomarkers May Determine Responsiveness to Ganite in Non-Hodgkin's Lymphoma
Apr 01, 2003: Genta Completes FDA Submission of New Drug Application for Ganite; (gallium nitrate injection)
Jan 03, 2003: Genta Announces Reactivation of New Drug Application (NDA) for Ganite and Initiation of CMC Regulatory Filings Submissions Intended to Enable Product Launch during 2003
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hypercalcemia Of Malignancy, Q3 2011
Products under Development for Hypercalcemia Of Malignancy – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Amgen Inc., 2011
Med Discovery SA, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Hypercalcemia Of Malignancy Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Hypercalcemia Of Malignancy, Q3 2011
Products under Development for Hypercalcemia Of Malignancy – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos